Cancer Focus Fund Invests $4.8 Million in March Biosciences to Support CAR-T Therapy for T-Cell Lymphoma
Houston-based scientists, entrepreneurs, clinical centers, manufacturers and investors collaborate to advance promising new approach for patients with few treatment option
Cancer Focus Fund invests $4.8M into Houston-based March Biosciences (Houston Business Journal)
The Cancer Focus Fund invested $4.8 million into March Biosciences, a cell therapy company that has already tapped some of Houston’s growing life sciences resources.
ImmunoGenesis Doses First Patient in Clinical Trial of Drug for Advanced Solid Tumors
The drug is the first that targets two antibodies with cytotoxic function designed to treat cancers that are resistant to existing immunotherapies
Houston Oncology Summit: MD Anderson’s Ferran Prat, VP of industry relations, talks about partnering
Ferran Prat describes advantages MD Anderson offers to drug developers, what makes a good partner, and science that interest him today.
Cancer Focus Fund Investing $4.5 Million in ImmunoGenesis to Support Drug Trial for Relapsed or Refractory Advanced Solid Tumors
ImmunoGenesis’ drug is a dual-specific antibody designed to treat tumors that are resistant to existing immunotherapy. CFF's investment will support a multi-site clinical trial of the drug being conducted at MD Anderson.
Cancer Focus Fund Invests $5 Million to Support Human Trial of ISA's Immunotherapy to treat Uveal Melanoma
Clinical Trial of PRAME-Targeting Immunotherapy ISA103 in Rare Ocular Cancer to be Conducted at MD Anderson Cancer Center
Israeli biotech company begins trial for cancer immuno-oncology solution
Nectin's product, NTX1088, blocks the harmful overexpression of PVR proteins, which occurs in tumors caused by lung, breast, throat and other cancers.